Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Innobation Bio Co. Ltd. maintains 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These cases are distributed among 2 distinct examiners, yet they are both located within 1 distinct art unit. This indicates that while the company interacts with different individuals, the technical oversight remains centralized within a single administrative group. Practitioners should focus on the specific requirements of this 1 art unit to streamline the company's biotechnology patenting process.
The busiest examiner for the company is STOICA, ELLY GERALD, who is responsible for 1 pending office action. With 2 pending actions in total, the company's prosecution workload is evenly split between the 2 distinct examiners. Because both actions are within the same art unit, the company can apply consistent technical arguments across both cases even though they are being reviewed by different people. This concentration in 1 art unit provides a stable environment for managing the company's current biotechnology intellectual property.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| DICKINSON, PAUL W | 1 | 63.1% | +9.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17791028 | COMPANION DIAGNOSIS BIOMARKER COMPOSITION AND COMPANION DIAGNOSIS KIT CONTAINING SAME | DICKINSON, PAUL W | 7d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575494 | ANTIBODY SPECIFIC FOR MESOTHELIN AND USES THEREOF | STOICA, ELLY GERALD | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575494 | ANTIBODY SPECIFIC FOR MESOTHELIN AND USES THEREOF | STOICA, ELLY GERALD | — | §112 | Non-Final OA | — | Pending | Dec 29, 2023 |
| 17791028 | COMPANION DIAGNOSIS BIOMARKER COMPOSITION AND COMPANION DIAGNOSIS KIT CONTAINING SAME | DICKINSON, PAUL W | 1618 | §101§102§112 | Final Rejection | 7d | Pending | Jul 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial